- Home
- RADX vs STTK Comparison
RADX vs STTK Comparison
Compare RADX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- STTK
- Stock Information
- Founded
- RADX 2021
- STTK 2016
- Country
- RADX Australia
- STTK United States
- Employees
- RADX N/A
- STTK N/A
- Industry
- RADX
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- RADX
- STTK Health Care
- Exchange
- RADX NYSE
- STTK Nasdaq
- Market Cap
- RADX 32.5M
- STTK 38.4M
- IPO Year
- RADX N/A
- STTK 2020
- Fundamental
- Price
- RADX $5.35
- STTK $0.73
- Analyst Decision
- RADX Strong Buy
- STTK Hold
- Analyst Count
- RADX 3
- STTK 4
- Target Price
- RADX $15.00
- STTK $3.00
- AVG Volume (30 Days)
- RADX 17.5K
- STTK 211.5K
- Earning Date
- RADX 02-26-2025
- STTK 08-12-2025
- Dividend Yield
- RADX N/A
- STTK N/A
- EPS Growth
- RADX N/A
- STTK N/A
- EPS
- RADX N/A
- STTK N/A
- Revenue
- RADX $204,609.00
- STTK $4,606,000.00
- Revenue This Year
- RADX N/A
- STTK N/A
- Revenue Next Year
- RADX N/A
- STTK N/A
- P/E Ratio
- RADX N/A
- STTK N/A
- Revenue Growth
- RADX N/A
- STTK 69.65
- 52 Week Low
- RADX $3.50
- STTK $0.69
- 52 Week High
- RADX $50.82
- STTK $4.00
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- STTK 38.74
- Support Level
- RADX N/A
- STTK $0.73
- Resistance Level
- RADX N/A
- STTK $0.92
- Average True Range (ATR)
- RADX 0.00
- STTK 0.07
- MACD
- RADX 0.00
- STTK 0.00
- Stochastic Oscillator
- RADX 0.00
- STTK 1.06
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.